
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
- Company’s patented desmopressin oral solution successfully passed pivotal bioequivalence study - - Company expects to submit New Drug Application (NDA) in April 2025 - DEER PARK, Ill., March 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” …